Download our new eBook - How to develop effective in vitro assays for early drug discovery
Scientists at Aurelia Bioscience Ltd have over 100 years experience in drug discovery gained at several blue chip pharmaceutical companies including Hoffmann La Roche, Smith Kline Beecham, Glaxo-Wellcome, AstraZeneca, ICI and UCB.
They have worked in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation drug discovery phases in both cellular and non-cellular assay formats. They have experience of a wide range of technologies designed to prosecute these activities in a scalable manner whilst bringing to bear technological developments that have the ability to probe ever further into the molecular interactions from which the drugs of the future may be identified.
Research areas worked in include respiratory disease, inflammatory disease, oncology, CNS-pain, rare disorders and diabetes, working on a range of molecular targets in these areas.
Gary Allenby, Kathy Dodgson and Kevin Hart are the founders of Aurelia Bioscience. They have decades of experience between them in early stage drug discovery, working with FLIPR, FMAT, EPIC label free, Envision based assays in both biochemical and cell-based assays.
Kevin Hart Ph.D.
Managing Director and Founder
Kevin is responsible for P&L, finance, governance and BD at Aurelia Bioscience. He gained a Ph.D. in Clinical Molecular Genetics at Guys Hospital, London prior to joining ICI Diagnostics, a genomics start-up company. He moved to ICI/Zeneca/AstraZeneca Pharmaceuticals (Alderley Park) where he worked as principal scientist and project/team leader in multi-disciplinary teams across a range of disease areas. He then took on management and leadership roles, moved to AstraZeneca R&D Charnwood before founding Aurelia Bioscience. Hart@aureliabio.com
Gary Allenby Ph.D.
Chief Scientific Officer and Founder
After gaining his Ph.D. from Edinburgh University in 1990 he joined Hoffmann La Roche USA investigating retinoid pharmacology. He joined the Lead Generation Section of Glaxo-Wellcome UK in 1996 gaining expertise in cell-based assay development, screening and automation. In 2000 he joined AstraZeneca, developing automation and evaluating and implementing new technologies on novel assay formats. Allenby@aureliabio.com
Kathy Dodgson MS.c.
Science Director and Founder
Kathy has over 20 years of industrial experience gained at Smith-Kline-Beecham and AstraZeneca. Kathy has worked on the development and implementation of new screening approaches including FMAT and recently label-free based screening. Kathy led the implementation of label-free cell-based screening within AstraZeneca.
She is a key opinion leader in the application of label free screening, presenting at global screening conferences and published articles on label-free in peer reviewed journals. Dodgson@aureliabio.com
Tony Flinn Ph.D.
Tony is a very experienced scientist and manager and a highly successful businessman. With B.Sc. and Ph.D. degrees in Chemistry, Tony has held a number of positions within both research and development, in addition to sales, marketing and general management in several large and small companies. Tony founded the award winning Onyx Scientific Ltd in 2000, subsequently managing an MBO and sale of the business in 2011.
He currently operates as a Non-Executive Director in a number of innovative companies.